View in EDS

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

Saved in:
Bibliographic Details
Title: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
Authors: Elimova E; Department of Gastrointestinal Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: elena.elimova@uhn.ca., Ajani J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burris H; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Denlinger CS; Department of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Iqbal S; Divison of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Kim JH; Division of Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea., Lee KW; Department of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea., Lin B; Section of Hematology-Oncology, Virginia Mason Medical Center, Seattle, WA, USA., Mehta R; Department of Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA., Oh DY; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Seol YM; Department of Internal Medicine, Pusan National University Hospital, Pusan National University College of Medicine, Busan, South Korea., Yang L; Jazz Pharmaceuticals, Palo Alto, CA, USA., Ozog MA; Jazz Pharmaceuticals, Palo Alto, CA, USA., Garfin PM; Jazz Pharmaceuticals, Palo Alto, CA, USA., Ku G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Jul; Vol. 26 (7), pp. 847-859. Date of Electronic Publication: 2025 Jun 02.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40473445
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Elimova+E%22">Elimova E</searchLink>; Department of Gastrointestinal Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: elena.elimova@uhn.ca.<br /><searchLink fieldCode="AU" term="%22Ajani+J%22">Ajani J</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Burris+H%22">Burris H</searchLink>; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Denlinger+CS%22">Denlinger CS</searchLink>; Department of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Iqbal+S%22">Iqbal S</searchLink>; Divison of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kang+YK%22">Kang YK</searchLink>; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+JH%22">Kim JH</searchLink>; Division of Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Lee+KW%22">Lee KW</searchLink>; Department of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.<br /><searchLink fieldCode="AU" term="%22Lin+B%22">Lin B</searchLink>; Section of Hematology-Oncology, Virginia Mason Medical Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Mehta+R%22">Mehta R</searchLink>; Department of Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Rha+SY%22">Rha SY</searchLink>; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Seol+YM%22">Seol YM</searchLink>; Department of Internal Medicine, Pusan National University Hospital, Pusan National University College of Medicine, Busan, South Korea.<br /><searchLink fieldCode="AU" term="%22Yang+L%22">Yang L</searchLink>; Jazz Pharmaceuticals, Palo Alto, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ozog+MA%22">Ozog MA</searchLink>; Jazz Pharmaceuticals, Palo Alto, CA, USA.<br /><searchLink fieldCode="AU" term="%22Garfin+PM%22">Garfin PM</searchLink>; Jazz Pharmaceuticals, Palo Alto, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ku+G%22">Ku G</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2025 Jul; Vol. 26 (7), pp. 847-859. <i>Date of Electronic Publication: </i>2025 Jun 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40473445
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(25)00287-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 847
    Titles:
      – TitleFull: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Elimova E
      – PersonEntity:
          Name:
            NameFull: Ajani J
      – PersonEntity:
          Name:
            NameFull: Burris H
      – PersonEntity:
          Name:
            NameFull: Denlinger CS
      – PersonEntity:
          Name:
            NameFull: Iqbal S
      – PersonEntity:
          Name:
            NameFull: Kang YK
      – PersonEntity:
          Name:
            NameFull: Kim JH
      – PersonEntity:
          Name:
            NameFull: Lee KW
      – PersonEntity:
          Name:
            NameFull: Lin B
      – PersonEntity:
          Name:
            NameFull: Mehta R
      – PersonEntity:
          Name:
            NameFull: Oh DY
      – PersonEntity:
          Name:
            NameFull: Rha SY
      – PersonEntity:
          Name:
            NameFull: Seol YM
      – PersonEntity:
          Name:
            NameFull: Yang L
      – PersonEntity:
          Name:
            NameFull: Ozog MA
      – PersonEntity:
          Name:
            NameFull: Garfin PM
      – PersonEntity:
          Name:
            NameFull: Ku G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1